Your Messages Inbox
Your Article Summary
See Latest ArticlesPositive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia
XenoPort, 09/18/09
GlaxoSmithKline and XenoPort, Inc. announced top–line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 for neuropathic pain associated with post–herpetic neuralgia in adults. In this study, subjects were randomized to receive placebo, 1200, 2400 or 3600 mg/day of GSK1838262 dosed twice a day.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09
Article Search
Sponsor